Versartis, Inc. (NASDAQ:VSAR) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Wednesday.

According to Zacks, “Versartis, Inc. operates as a biotechnology company. It develops therapeutic proteins for the treatment of metabolic diseases and endocrine disorders. The Company is developing VRS-317, a long-acting recombinant human growth hormone, which is in Phase 2a clinical trials for the treatment of growth hormone deficiency. Versartis, Inc. is headquartered in Redwood City, California. “

Several other research firms also recently weighed in on VSAR. BidaskClub raised Versartis from a “hold” rating to a “buy” rating in a report on Monday, July 24th. Piper Jaffray Companies set a $26.00 target price on Versartis and gave the company a “buy” rating in a report on Tuesday, June 27th. Canaccord Genuity set a $28.00 target price on Versartis and gave the company a “buy” rating in a report on Friday, July 28th. Cantor Fitzgerald set a $34.00 target price on Versartis and gave the company a “buy” rating in a report on Thursday, July 27th. Finally, Cowen and Company reissued an “outperform” rating and issued a $45.00 target price on shares of Versartis in a report on Wednesday, August 23rd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $27.88.

Versartis (NASDAQ:VSAR) opened at 19.00 on Wednesday. The stock’s market cap is $675.98 million. The firm’s 50-day moving average price is $17.99 and its 200 day moving average price is $18.37. Versartis has a 12 month low of $9.05 and a 12 month high of $24.00.

Versartis (NASDAQ:VSAR) last posted its earnings results on Thursday, July 27th. The biopharmaceutical company reported ($1.04) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.84) by $0.20. On average, analysts anticipate that Versartis will post ($3.49) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Zacks Investment Research Upgrades Versartis, Inc. (VSAR) to Hold” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this report can be viewed at https://www.thecerbatgem.com/2017/09/01/zacks-investment-research-upgrades-versartis-inc-vsar-to-hold.html.

Institutional investors have recently modified their holdings of the stock. First Quadrant L P CA bought a new position in shares of Versartis during the second quarter valued at about $155,000. Bank of America Corp DE boosted its position in shares of Versartis by 46.3% in the first quarter. Bank of America Corp DE now owns 9,482 shares of the biopharmaceutical company’s stock valued at $203,000 after buying an additional 3,001 shares during the period. Tudor Investment Corp ET AL bought a new position in shares of Versartis during the second quarter valued at about $218,000. Numeric Investors LLC bought a new position in shares of Versartis during the second quarter valued at about $246,000. Finally, Voya Investment Management LLC boosted its position in shares of Versartis by 26.1% in the second quarter. Voya Investment Management LLC now owns 14,960 shares of the biopharmaceutical company’s stock valued at $261,000 after buying an additional 3,094 shares during the period. Hedge funds and other institutional investors own 78.77% of the company’s stock.

About Versartis

Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.

Analyst Recommendations for Versartis (NASDAQ:VSAR)

Receive News & Stock Ratings for Versartis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis Inc. and related stocks with our FREE daily email newsletter.